Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMany people starting semaglutide for weight loss notice changes in how energised they feel, and the picture is more nuanced than a simple boost or dip. Clinical trial data show that fatigue is one of the reported side effects during early treatment, yet many participants in STEP 1 — the pivotal 68-week semaglutide trial published in the New England Journal of Medicine — described improved vitality and quality of life as weight came off over time. These are prescription-only medicines, so any discussion of whether semaglutide is right for you is one for a registered prescriber, not a web page.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial enrolled 1,961 adults with obesity or overweight and tracked outcomes over 68 weeks. Fatigue appeared in the adverse-event data for the semaglutide group, not a dramatic signal, but consistent enough to be listed as a recognised side effect. The NHS semaglutide medicines page confirms this, noting tiredness and headache among the common effects people report, particularly in the weeks after starting or after a dose increase.
The mechanism makes physiological sense. Semaglutide slows gastric emptying, reduces appetite strongly, and shifts the body's energy balance. In the short term, eating considerably less while your metabolism is still calibrated for a higher intake can leave some people feeling flat. That is not a sign the medicine is failing. It is usually the adjustment period doing what it is supposed to do.
What the trial data also captured, further into the 68 weeks, was a different story: participants reported meaningful improvements in health-related quality of life, including physical functioning and vitality, as substantial weight loss accumulated. So the trajectory for many people runs from an early dip toward a later lift. Knowing that does not make the first few weeks easier, but it gives the picture context.
The gastrointestinal side effects (nausea, loose stools, reflux) are the most commonly discussed aspect of early semaglutide treatment, and they pull energy down indirectly. If you are nauseous for several days after a dose step-up, you eat less, drink less, and sleep worse. The tiredness that follows is not mysterious. It is the downstream effect of feeling unwell, not a pharmacological property of semaglutide itself.
There is a practical nutrition angle here that our clinical team raises regularly. When appetite suppression is strong, total food intake can drop sharply. If that reduction lands mostly on protein and complex carbohydrates (the foods that sustain steady energy) rather than on excess fat, the shortfall shows up as afternoon fatigue or brain fog. Staying deliberate about what you eat, even when you are not particularly hungry, matters more on semaglutide than it does when appetite is unrestricted.
Hydration is an underappreciated factor. Semaglutide-related nausea can reduce the urge to drink, and mild dehydration compounds low energy reliably. The NHS guidance on weight management injections is clear that patients should be supported to manage these effects, and that the right support includes dietary and lifestyle coaching alongside the medicine, not just the prescription itself.
For many people, yes, and the improvement can be significant. Carrying excess weight places real demands on the cardiovascular and musculoskeletal systems: every flight of stairs, every walk to the school gates. As that load reduces, physical energy tends to rise. Participants in the longer semaglutide trials reported better physical functioning scores at 68 weeks than at baseline, a finding that aligns with what clinicians observe in practice.
People who are curious about how this unfolds over the full treatment course will find more detail on the energy improvements people notice on Wegovy page, which covers what typically changes month by month. There is also a dedicated page examining persistent lack of energy on Wegovy for anyone whose fatigue is not resolving on the expected timeline.
One point worth flagging: energy is not listed among the primary outcomes semaglutide is licensed or prescribed to produce. It is a consequence (welcome or otherwise) of the biological changes underway. Any concern about whether your energy levels are appropriate at your current stage of treatment, including whether you are on the right dose for your progress, is worth exploring on the wegovy levels page before raising it with your prescriber at the next clinical review.
Several factors within your control have a disproportionate effect on how you feel day to day. The NHS England guidance on weight management injections is explicit that the medicine works best within a structured programme of dietary and activity support, and that framing applies to energy too.
Prioritise protein at every meal, even small ones, it blunts muscle loss during caloric restriction and supports steadier blood sugar, both of which feed into consistent energy. Gentle activity, even short walks, tends to help more than rest during the middle weeks. Sleep quality often improves as weight falls, but it may dip initially if GI discomfort disturbs nights.
Timing matters in small ways too. If you inject on a Monday and the first few days of each week are reliably more tiring, that pattern is worth noting and discussing with your prescriber, adjusting injection day is a straightforward conversation. Some people find that planning physically demanding days around their injection schedule, rather than against it, makes the early months considerably more manageable. Even something as simple as aligning injection day with a quieter patch in the week, rather than before a run of demanding days, can ease the adjustment.
For a fuller picture of how semaglutide works as a medicine, the semaglutide overview page covers its mechanism and UK licensing in detail. If you are comparing how energy changes on Wegovy versus other treatment options, the Wegovy treatment page is a good starting point. Questions about cost and what treatment includes are addressed on the Wegovy cost page. And if you are still deciding whether semaglutide is the right route for you, the treatment overview page lays out the full picture of available options.
If you would like a prescriber to assess whether semaglutide is clinically appropriate for you, start a free consultation with our team.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.